Pottstown Medical Specialists, Inc. (PMSI) has court-approved procedures to pursue a sale of acquired assets, with Thomas Jefferson University serving as the stalking horse purchaser. The September 30, 2026 order approves the bidding process and bid protections and schedules consideration of final sale approval for October 30. Competing bids are due October 22, with an auction scheduled for October 23 if another qualified bid is received. Sale procedures order, pp. 4–9
Jefferson is also the authorized postpetition lender. A September 29 final order authorizes up to $5,887,301 in new-money principal commitments, plus capitalized interest, fees, and costs. The commitment represents authorized financing capacity; it does not establish how much PMSI has borrowed. Final financing order, pp. 2, 12–13
This account describes the September 29 financing order and September 30 sale filings. The sale dates below are scheduled milestones subject to authorized changes or adjournment.
The court approved Jefferson's selection as stalking horse purchaser and the form of the asset purchase agreement. Jefferson's bid is deemed qualified and provides the baseline for soliciting higher or otherwise better offers. The order makes performance under the agreement subject to the competing-offer process and entry of a sale order. Sale procedures order, pp. 4–7
The approved bid protections include a breakup fee capped at 3% of the purchase price and expense reimbursement capped at $250,000. They are payable from sale proceeds at the closing of an alternate transaction under the order's conditions. Sale procedures order, pp. 7–8
At an auction, Jefferson may credit bid the breakup fee, expense reimbursement, and financing obligations outstanding as of closing as part of an overbid. Any such credit bid must provide for full cash repayment of outstanding prepetition loan obligations at closing. Sale procedures order, p. 9
A competing buyer must address operating liquidity
The final financing order identifies Thomas Jefferson University, on behalf of itself, its assigns, and controlled affiliates, as the lender. It states that $1,873,879 was available upon entry of the interim order within the larger $5,887,301 principal commitment. Borrowing and use of proceeds remain subject to the financing documents, court orders, and approved budget. Final financing order, pp. 2, 12–13
A competing bidder must provide and obtain approval of replacement financing with a lump-sum advance equal to the then-unfunded availability under the existing facility upon entry of the sale order. The replacement loan must have substantially similar terms, with liens, claims, and priorities junior to existing liens and claims, including those of the existing lender. The procedures connect that funding to operating the practice through December 31, 2026 and consummating a closing effective January 1, 2027. Sale procedures, pp. 23–24
The procedures require a competing bid to specify cash of at least approximately $9,647,398 and any other offered consideration. The cash requirement incorporates listed closing obligations and bidding requirements. Those include an approximately $200,000 unsecured-creditor carveout, cure costs capped at $150,000, bid protections, and a $250,000 minimum bid increment. The procedures also identify wind-down funding capped at $1.9 million and expressly include that amount within the financing-obligation component. Sale procedures, pp. 23–24
PMSI's business and reported liquidity
Interim chief executive Timothy Rimmer described a multispecialty medical group employing more than 145 people, with offices in Pottstown, Boyertown, Collegeville, and Royersford. His declaration reported approximately $96,000 in cash and $6.25 million in accounts receivable as of August 30, 2026. Rimmer declaration, ¶¶ 10–12
Scheduled sale milestones
The September 30 notice sets the following schedule. If PMSI receives no qualified bid other than Jefferson's, the procedures order provides for cancellation of the auction and pursuit of final approval of Jefferson's agreement at the sale hearing. Sale notice, pp. 2–4; sale procedures order, p. 9
Scheduled milestone
Date and time, prevailing Eastern time
Bid deadline
October 22, 2026, 4:00 p.m.
Sale-objection deadline
October 22, 2026, 4:00 p.m.
Cure/assignment-objection deadline
October 22, 2026, 4:00 p.m.
Auction, if required
October 23, 2026, 10:00 a.m.
Adequate-assurance objection deadlines
October 28, 2026, 4:00 p.m.
Sale hearing
October 30, 2026, 9:30 a.m.
Scheduled October sale milestones.
The sale notice identifies Omni Agent Solutions as the noticing agent. Its PMSI restructuring website provides case information. The scheduled sale hearing will consider approval of a sale to Jefferson or another prevailing bidder. Sale notice, pp. 2–4
Sources
Sale procedures order, pp. 4–9 /documents/8963571a-c98b-4625-8a5c-c75c4fb54073/
Final financing order, pp. 2, 12–13 /documents/48228c2e-85fc-4188-ad92-0f7d0ea6c9ed/
This article was researched and written with AI assistance, using court filings, public records, and news sources. AI-generated content can contain errors. Verify all information against primary sources before relying on it. This is not legal or financial advice. See the disclaimer.